Kodiak Sciences Inc.
Financials
Valuation Metrics
Kodiak Sciences Inc.'s Market Cap is $6.11B. At end of 2025 it was $1.49B. Ranked #1179 of 3,118 in US market (top 38%), #386 of 1,474 on NASDAQ (top 26%), #67 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 25%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $6.11B | US#1,179/3,118 Sec#67/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-242M | US—/3,118 Sec—/265 |
| Total Assets | $257M | US#2,935/3,118 Sec#222/265 |
| Net Assets | $61M | US#2,835/3,118 Sec#218/265 |
| Employees | 141 | US#2,550/3,118 Sec#152/265 |
| Value | ||
| P/B | 99.99x | US#2,896/3,118 Sec#233/265 |
| FCF Yield | -2.62% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROA | -94.23% | US#3,049/3,118 Sec#254/265 |
| Financial Health | ||
| Debt Ratio | 320.34% | US#2,147/3,118 Sec#213/265 |
| Total Debt | $96M | US#2,443/3,118 Sec#122/265 |
| FCF | $-160M | US#2,730/3,118 Sec#189/265 |
| Cash | $126M | US#2,054/3,118 Sec#148/265 |
| Current Ratio | 2.49x | US#961/3,118 Sec#201/265 |
| Performance | ||
| 1Y Return | 438.47% | US#11/3,118 Sec#5/265 |
| 1M Return | 3.36% | US#1,288/3,118 Sec#76/265 |
| From 52W High | -6.13% | US#376/3,118 Sec#27/265 |
| 1Y MDD | -36.24% | US#1,721/3,118 Sec#96/265 |
| Trading | ||
| Volume | 585,370 shares | US#1,974/3,118 Sec#193/265 |
| Trading Value | $57M | US#1,226/3,118 Sec#73/265 |
| Per Share | ||
| EPS | $-3.87 | US—/3,118 Sec—/265 |
| BPS | $0.98 | US#2,693/3,118 Sec#203/265 |
Company Info
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.